Azadeh Vahdat

Associate, Foreign Qualified Lawyer

Azadeh Vahdat

Azadeh is an Australian qualified solicitor and joined EIP from one of the largest specialist IP firms in Australia. She has advised both innovator and generic multi-national pharmaceutical companies throughout all stages of contentious patent proceedings, with experience in small-molecules, biologics and biosimilars. She notably represented ICOS (Eli Lilly) in a high profile case in the Federal Court of Australia.

Azadeh has a BSc in Biomedical Science and a Juris Doctor from Murdoch University, and a Graduate Diploma of Legal Practice from the Australian College of Law.


  • Apotex Pty Ltd v ICOS Corporation (No 3) [2018] FCA 1204
  • Apotex Pty Ltd v ICOS Corporation [2017] FCA 466

Published articles

  • August 2023
    EIP Updates, Unnamed inventors can benefit from s.40 employee compensation, but only if you get there in time (link)
  • January 2023
    LSIPR, Why Novartis lost its treatment dispute with Teva (link)
  • January 2023
    EIP Updates, Court of Appeal refuses Arrow declaratory relief for Teva in a stand against forum shopping and jurisdictional imperialism (link)
  • December 2022
    EIP Updates, Novartis overloaded with reasons its iron overload treatment Exjade is obvious and not infringed by Teva (link)
  • August 2022
    Company, Women in Law: A Legal Timeline, in celebration of Women’s Equality Day (link)
  • June 2022
    Update, Patents Court affirms power to grant injunctions for pre-grant patents, but Novartis loses on interim relief and refused permission to appeal by Birss LJ for Gilenya® (link)

Education and qualifications

  • 2015 — 2016
    Graduate Diploma of Legal Practice , College of Law (Australia)
  • 2011 — 2014
    Juris Doctor, Murdoch University
  • 2007 — 2010
    BSc Biomedical Science, Murdoch University

Career history

  • 2020 — present
    Associate, EIP
  • 2016 — 2019
    Lawyer, Wrays
  • 2014 — 2016
    Analyst, Deloitte

Languages spoken

  • Farsi (fluent)